Individual Patient Supply (UK): how it works and where it is recognized
A cross-border regulatory framework for supplying an unregistered or off-label medicine to a specific patient, on the order of a treating physician, under a defined permit issued by the destination-country medicines regulator.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
What Individual Patient Supply UK is
Origin and authorising body. United Kingdom, under Regulation 167 of the Human Medicines Regulations 2012. The authorising body for each individual case is the Medicines and Healthcare products Regulatory Agency (MHRA), acting under that jurisdiction's pharmacy or medicines legislation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Legal basis. Regulation 167 of the Human Medicines Regulations 2012 permits the supply of unlicensed medicines to meet the special clinical needs of an individual patient on the order of a doctor, dentist, supplementary prescriber, nurse independent prescriber, pharmacist independent prescriber, or optometrist independent prescriber. Suppliers must hold either a manufacturer's specials licence (MS) or a wholesale dealer's licence (WL) with permission to deal in unlicensed medicines.
Individual Patient Supply (UK) is the regulatory architecture under which UK prescribers obtain unlicensed medicines for named patients. The framework allows three sourcing routes: a specials manufacturer (UK or imported), a wholesale dealer who imports unlicensed medicines, or direct import by a specials manufacturer. The MHRA does not authorise each individual case; instead, it authorises the suppliers and audits their practice. The prescribing clinician carries clinical responsibility, the supplier carries quality responsibility.
The framework is widely used in UK specialty practice for oncology, paediatrics, dermatology, and rare diseases. Specialist hospitals such as Great Ormond Street, the Royal Marsden, Christie, Royal Free, and University College London Hospitals operate established workflows with named specials suppliers. The MHRA publishes a register of licensed specials manufacturers and wholesale dealers authorised to supply unlicensed medicines. The framework has been the operative individual-patient supply mechanism since 2012, when the Human Medicines Regulations consolidated and modernised the prior Medicines Act 1968 architecture.
This page consolidates Reserve Meds's operational view of the Individual Patient Supply (UK) framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Individual Patient Supply (UK)-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.
Reserved for you.
Who can use Individual Patient Supply UK
Individual Patient Supply is used by UK prescribers (NHS or private) on behalf of UK patients. The prescription must specify the patient and the clinical justification, and the supplier must verify the prescriber's registration before supply. Cross-border patients from outside the UK cannot use the framework directly; UK-based patients with cross-border clinical scenarios may use it for the UK leg of supply.
In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.
Drug categories typically covered under Individual Patient Supply UK
Unlicensed paediatric formulations of adult-licensed medicines, US-licensed oncology agents not yet UK-licensed, rare-disease biologics, dermatology specialty agents, and medicines withdrawn from the UK market still available elsewhere.
The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Individual Patient Supply (UK) import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.
Country compatibility
The table below summarises how the Individual Patient Supply (UK) framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Individual Patient Supply (UK) dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Individual Patient Supply (UK) clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.
| Country | Local pathway equivalent | Accepts Individual Patient Supply (UK) dossiers? | Typical timeline | Local regulator |
|---|---|---|---|---|
| Bahrain | NHRA Compassionate / Special Import Permit | Indirect (reference precedent only) | 5 to 15 business days | NHRA |
| Egypt | EDA Single-Patient Import (Decree 425) | Indirect (reference precedent only) | 10 to 25 business days | EDA |
| India | Rule 36 personal-use import (D&C Rules 1945) | Indirect (reference precedent only) | 7 to 21 business days | CDSCO |
| Jordan | JFDA Compassionate / Special Use Import | Indirect (reference precedent only) | 10 to 20 business days | JFDA |
| Kuwait | MoH Unregistered Medicine Import Permit | Indirect (reference precedent only) | 10 to 20 business days | KDFC (MoH) |
| Lebanon | MoPH Special Import for Named Patient | Indirect (reference precedent only) | 10 to 25 business days | MoPH |
| Oman | MoH Compassionate / Named-Patient Import | Indirect (reference precedent only) | 10 to 20 business days | MoH-DGPADC |
| Qatar | MoPH Single-Patient Unregistered Drug Import | Indirect (reference precedent only) | 10 to 20 business days | MoPH-DPA |
| Saudi Arabia | SFDA Personal Importation Permit | Indirect (reference precedent only) | 10 to 25 business days | SFDA |
| United Arab Emirates | EDE Unregistered Medicine Import Permit | Indirect (reference precedent only) | 5 to 15 business days | EDE |
Notes. "Indirect" means the destination regulator does not directly accept Individual Patient Supply (UK) authorisation as the legal basis for import but does recognise a Individual Patient Supply (UK) authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).
Documentation required
A Individual Patient Supply UK application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).
- UK prescriber's prescription with clinical justification.
- Patient identifier and clinical history.
- Supplier's batch documentation and chain-of-custody.
- Informed consent for unlicensed-medicine use.
- Where applicable, ethics committee notification for paediatric or rare-disease cases.
- Prescriber registration verification by the supplier.
Typical timeline
Routine specials supply: 1 to 3 weeks from prescription to dispensing in the UK. Imported specials (US, EU, other): 3 to 6 weeks depending on the source country and the supplier's existing relationships. Cross-border patients using parallel home-country frameworks complete in 4 to 8 weeks end-to-end.
Costs and reimbursement
NHS reimbursement for specials is governed by the specials tariff and varies by formulation; private prescriptions are paid at the supplier's cost. Cross-border patients pay the relevant per-country acquisition cost plus logistics, customs, dispensing, and coordinator fees.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Individual Patient Supply (UK) cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.
For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.
Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.
Next step
If your treating physician has identified a clinical need that fits the Individual Patient Supply (UK) framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.